Drug Profile
Research programme: nucleic acid therapeutics - ANRis Pharma
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator ANRis Pharma
- Class Macromolecular substances; Nucleic acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Kidney disorders
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Cancer in Canada
- 28 Oct 2019 No recent reports of development identified for research development in Kidney-disorders in Canada
- 15 Sep 2015 Research programme: nucleic acid therapeutics - ANRis Pharma is available for licensing as of 15 Sep 2015. http://anrispharma.com/